Clinical Trials Browser

Unknown × olaparib × Clear all

NCT02489006 2024-01-17

NEO

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05629429 2024-01-17

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT02229656 2023-11-07

Olaparib and Radiotherapy in Head and Neck Cancer

Phase 1 Unknown

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms

NCT04042831 2023-10-13

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Phase 2 Unknown

Gastrointestinal

Bile Duct Neoplasms

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03741426 2023-06-07

WIRE

Phase 2 Unknown

Carcinoma, Renal Cell

NCT04091204 2023-03-24

MITO 31

Phase 2 Unknown

Ovarian Neoplasms

NCT05201612 2023-02-24

PEMBROLA

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT04633902 2022-12-06

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Phase 2 Unknown

Melanoma

NCT05167175 2022-10-25

The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation

Phase 2 Unknown

Prostatic Neoplasms

NCT03278717 2022-09-27

ICON9

Phase 3 Unknown

Ovarian Neoplasms

NCT04015739 2022-08-17

BOLD

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Recurrence

NCT04641728 2022-08-09

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT05440578 2022-07-01

First-line Olaparib Combined With Bevacizumab Maintenance Therapy

Ovarian Neoplasms

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms

NCT03570437 2022-03-02

COPELIA

Phase 2 Unknown

GynecologicSarcoma

Carcinosarcoma, Neoplasms, Endometrial Neoplasms

NCT05262608 2022-03-02

PROspect

Phase 2 Unknown

Prostatic Neoplasms

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

Phase 2 Unknown

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02446704 2022-02-07

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

Phase 1/2 Unknown

Small Cell Lung Carcinoma

NCT05081765 2021-10-18

The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib

Hyperglycemia, Ovarian Neoplasms

NCT05044091 2021-09-14

HOPEI

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

Uterine Neoplasms, Endometrial Neoplasms

NCT02822157 2021-01-29

CLIO

Phase 2 Unknown

Carcinoma, Ovarian Epithelial

NCT04582552 2021-01-20

ROMP

Ovarian Neoplasms

NCT04566952 2020-10-30

ANLOLA

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT04261465 2020-02-07

NUVOLA

Phase 2 Unknown

High Grade Serous Ovarian Cancer

NCT01682772 2019-08-15

TOPARP

Phase 2 Unknown

Adenocarcinoma

NCT03829345 2019-07-08

SOLAR

Phase 2 Unknown

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

Advanced Breast Cancer

NCT01788332 2018-10-26

PIN

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01650376 2018-03-23

Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

Phase 1/2 Unknown

Ovarian Neoplasms, Recurrence, Uterine Neoplasms

NCT02684318 2017-06-22

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

Phase 1/2 Unknown

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02681562 2016-02-15

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01460888 2013-08-19

ROCOCO

Phase 1 Unknown

Gastrointestinal

Esophageal Neoplasms